Cannabis Sativa Acquires 51% of PrestoDoctor, A Premier Medical Marijuana Telemedicine Platform
MESQUITE, NV / ACCESSWIRE / August 2, 2017 / Cannabis Sativa. Inc. (OTCQB:CBDS) announced today that the Company has acquired a controlling interest in PrestoCorp (a.k.a. PrestoDoctor), an online telemedicine platform providing access to knowledgeable physicians for a safe and confidential way to get a medical marijuana recommendation using secure video conferencing technology (https://prestodoctor.com).
Appointments through PrestoDoctor’s website are generally completed in 10-15 minutes, and can be scheduled and completed in the same day. This convenience eliminates the need for patients to travel to an in-person appointment or wait in line at a clinic. More than 40,000 users have registered to consult with PrestoDoctor’s 15+ licensed physicians across the United States. PrestoDoctor currently offers services in California and Nevada, and is actively targeting expansion into multiple additional states in the coming months.
President David Tobias says:
“We are pleased to bring PrestoDoctor on board as a subsidiary of Cannabis Sativa. Combining our resources should be a great benefit to both companies. We are eager to assist PrestoDoctor in the roll out of their medical marijuana programs in several new states this year, and hope to see the continued growth of PrestoDoctor for years to come. We believe telemedicine is the future.”
PrestoDoctor was founded by an experienced Silicon Valley based team, with Kyle Powers previously at Google,IBM, PayPal, and ClearSlide, and Robert Tankson previously with Google, ClearSlide, and McCullough & Associates.
Cannabis Sativa, Inc. Awarded Patent for "Ecuadorian Sativa" Cannabis Plan
MESQUITE, NV / ACCESSWIRE / December 21, 2016 / Cannabis Sativa, Inc. (CBDS) announced that on December 20, 2016, the company's subsidiary was awarded Patent PP27,475 for a Cannabis Plant named "Ecuadorian Sativa".
"Equadorian Sativa" has been shown in laboratory testing by Steephill Labs to have a Limonene level that is extraordinarily high at a level of 4.53, 10 to 20 times the usual range. This sets "Equadorian Sativa" apart from other varieties in its odor, the effects on mood and mentation and its medical qualities.
The objective of the breeding, which produced this novel plant strain nicknamed "CTA", was primarily to develop a plant having the following characteristics: (a) medicinal properties that included hypotensive activity; (b) psychoactive properties that motivated and energized, rather than creating lethargy, sleepiness, and (c) increased food consumption.
Anecdotally, there are indications that its use may prevent some cancers and may cause apoptosis of cancer cells in vivo. There is a good possibility that the high levels of limonene may slow down the build-up of plaque in the arteries and reduce the effect of low-density lipo-proteins on the circulatory system. Indications are that "Ecuadorian Sativa" has many medical qualities that make it an important tool to maintain health and deal with illness.
"Our patience is now rewarded with the issuance of Patent PP27,475". "This patent will open up new areas for research and opportunities for CBDS", said CEO Mike Gravel.
This plant was derived from a female said to be of a strain called colloquially, "Celestial Temple Sativa" an individual grown in Ecuador that as a solitary plant reached a height of 23 feet. The male parent is said to have been of a strain known colloquially as "Island Sweet Skunk".
The Company's President David Tobias said, "This is a major accomplishment and is a tribute to the foresight and perseverance of management to solidify Cannabis Sativa's contribution to the maturing Cannabis industry."